Review of gas hydrate anti-agglomerant screening techniques

DC Salmin, D Estanga, CA Koh - Fuel, 2022 - Elsevier
Gas hydrates present a major flow assurance challenge due to the relatively fast timescales
at which they can form, agglomerate, and plug a subsea flowline, resulting in loss of …

Blood-brain barrier-supported neurogenesis in healthy and diseased brain

…, OL Lopatina, YK Komleva, VV Salmin… - Reviews in the …, 2017 - degruyter.com
Adult neurogenesis is one of the most important mechanisms contributing to brain development,
learning, and memory. Alterations in neurogenesis underlie a wide spectrum of brain …

[HTML][HTML] Plasticity of adipose tissue-derived stem cells and regulation of angiogenesis

…, NA Malinovskaya, AN Shuvaev, VV Salmin… - Frontiers in …, 2018 - frontiersin.org
Adipose tissue is recognized as an important organ with metabolic, regulatory, and plastic
roles. Adipose tissue-derived stem cells (ASCs) with self-renewal properties localize in the …

Nusinersen in type 1 spinal muscular atrophy: twelve‐month real‐world data

…, B Berti, G Brigati, P Tacchetti, F Salmin… - Annals of …, 2019 - Wiley Online Library
Objective The aim of the study was to report 12‐month changes after treatment with nusinersen
in a cohort of 85 type I spinal muscular atrophy patients of ages ranging from 2 months to …

Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen

…, S Messina, F Rao, E Roma, F Salmin… - The Journal of …, 2020 - Elsevier
Objective To evaluate the effects of nusinersen on respiratory function of patients with type 1
spinal muscular atrophy. Study design Observational, longitudinal cohort study. We …

[HTML][HTML] Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch …

…, R Cutrera, C Chierchi, MB Chiarini, F Salmin… - …, 2023 - thelancet.com
Background Efficacy and safety of onasemnogene abeparvovec (OA) for Spinal Muscular
Atrophy infants under 7 months and <8.5 kg has been reported in clinical trials. This study …

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients

…, G Brigati, P Tacchetti, F Salmin… - Annals of Clinical …, 2021 - Wiley Online Library
Objective The aim of this paper was to report the 2‐year follow‐up in type I patients treated
with Nusinersen and to assess whether possible changes in motor function are related to the …

[HTML][HTML] Blood–brain barrier and neurovascular unit in vitro models for studying mitochondria-driven molecular mechanisms of neurodegeneration

…, AV Morgun, AN Shuvaev, VV Salmin… - International Journal of …, 2021 - mdpi.com
Pathophysiology of chronic neurodegeneration is mainly based on complex mechanisms
related to aberrant signal transduction, excitation/inhibition imbalance, excitotoxicity, synaptic …

Technical design report for PANDA electromagnetic calorimeter (EMC)

…, VK Rodionov, YN Rogov, RA Salmin… - arXiv preprint arXiv …, 2008 - arxiv.org
This document presents the technical layout and the envisaged performance of the
Electromagnetic Calorimeter (EMC) for the PANDA target spectrometer. The EMC has been …

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy

…, A d'Amico, C Bruno, F Salmin… - Annals of clinical …, 2022 - Wiley Online Library
The study reports real world data in type 2 and 3 SMA patients treated for at least 2 years
with nusinersen. Increase in motor function was observed after 12 months and during the …